The SGLT2 inhibitor dapagliflozin has been indicated for the treatment of type 2 diabetes since 2012 and is also indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction and for the treatment of chronic kidney disease. Sodium glucose co-transporter 2 (SGLT2) inhibitors act to improve glycaemic control by reducing glucose reabsorption and increasing urinary glucose excretion. if you take dapagliflozin for your type 1 diabetes, your specialist will help you safely discontinue this treatment – you will need to monitor your blood glucose levels more closely to prevent hypoglycaemia or hyperglycaemia in the transition.this decision was not linked to a new safety issue and other patients using dapagliflozin for type 2 diabetes, heart failure, or chronic kidney disease can continue taking their medicine as recommended by a healthcare professional.the manufacturer of dapagliflozin (Forxiga) has voluntarily withdrawn its use in type 1 diabetes.always seek advice from your doctor or diabetes team before making changes to your diabetes medicines.report suspected adverse drug reactions associated with use of dapagliflozin on a Yellow CardĪdvice for healthcare professionals to give to patients and carers:.additional risk minimisation materials to mitigate the risks in patients with type 1 diabetes are no longer available.diabetic ketoacidosis is a known risk with use of dapagliflozin in all patients with diabetes, but it occurs more frequently in patients with type 1 diabetes than those with type 2 diabetes.an increased insulin dose may be needed, which should be undertaken carefully to minimise the risk of hypoglycaemia or hyperglycaemia.after stopping dapagliflozin treatment, frequent blood glucose monitoring is recommended.dapagliflozin should be reviewed and discontinued in patients with type 1 diabetes by or in consultation with a physician specialised in diabetes care as soon as clinically practical.the removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged.dapagliflozin 5 mg is no longer authorised for the treatment of patients with type 1 diabetes mellitus.

No longer human book review